Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 12, 2015, Pages H1575-H1582

  Heilman, Rachel P ^a   Lagoski, Megan B ^a   Lee, Keng Jin ^a   Taylor, Joann M ^a   Kim, Gina A ^a   Berkelhamer, Sara K ^a   Steinhorn, Robin H ^b   Farrow, Kathryn N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclic nucleotides; PDE5; Pulmonary hypertension; Right ventricle

Indexed keywords

CYCLIC GMP; CYCLIC NUCLEOTIDE; PHOSPHODIESTERASE V; SILDENAFIL; ANTIHYPERTENSIVE AGENT; CYCLIC AMP; PDE5A PROTEIN, MOUSE; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPEROXIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOPHYSIOLOGY; SECOND MESSENGER; TIME; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEART VENTRICLES; HYPEROXIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SECOND MESSENGER SYSTEMS; SILDENAFIL CITRATE; SULFONAMIDES; TIME FACTORS; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84931088635     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00569.2014     Document Type: Article

References (46)

1. An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, Kim HS, Choi JH, Noh CI, Yun YS. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Kor Circ J 40: 131–136, 2010.
2. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 10: 1158–1165, 2008.
3. Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 180: 1122–1130, 2009.
4. Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol 27: 8–16, 2014.
5. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355: 343–353, 2006.
6. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117: 1077–1083, 2006.
7. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD, Investigators S. STARTS-2: long-term survival with oral Sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 129: 1914–1923, 2014.
8. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125: 324–334, 2012.
9. Berkelhamer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 37: 124–131, 2013.
10. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135: 794–804, 2009.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976.
12. Check J, Gotteiner N, Liu X, Su E, Porta N, Steinhorn R, Mestan KK. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol 33: 553–557, 2013.
13. Fanaroff AA, Wright LL, Stevenson DK, Shankaran S, Donovan EF, Ehrenkrans RA, Younes N, Korones SB, Stoll BJ, Tyson JE, Bauer CR, Oh W, Lemons JA, Papile LA, Verter J. Very-Low-Birth-Weight Outcomes of the National-Institute-of-Child-Health-and-Human-Develop-ment Neonatal Research Network, May 1991 through December 1992. Am J Obstet Gynecol 173: 1423–1431, 1995.
14. Farrow KN, Lakshminrusimha S, Czech L, Groh BS, Gugino SF, Davis JM, Russell JA, Steinhorn RH. SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 299: L109–L116, 2010.
15. Farrow KN, Lee KJ, Perez M, Schriewer JM, Wedgwood S, Laksh-minrusimha S, Smith CL, Steinhorn RH, Schumacker PT. Brief hyperoxia increases mitochondrial oxidation and increases phosphodies-terase 5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal 17: 460–470, 2012.
16. Gien J, Seedorf GJ, Balasubramaniam V, Markham N, Abman SH. Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling. Am J Respir Crit Care Med 176: 1146–1153, 2007.
17. Hammond J, Balligand JL. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol 52: 330–340, 2012.
18. Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedja D, Gabrielson KL, Molkentin JD, Kass DA, Takimoto E. Phosphodies-terase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 81: 301–309, 2009.
19. Janssen W, Schermuly RT, Kojonazarov B. The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. Exp Physiol 98: 1274–1278, 2013.
20. Kass DA. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Current Heart Fail Reports 9: 192–199, 2012.
21. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120: 1260–1269, 2007.
22. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355: 354–364, 2006.
23. Lee DI, Kass DA. Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology 27: 248–258, 2012.
24. Lee KJ, Berkelhamer SK, Kim GA, Taylor JM, O’Shea KM, Stein-horn RH, Farrow KN. Disrupted pulmonary artery cGMP signaling in mice with hyperoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 50: 369–378, 2014.
25. Lee KJ, Berkelhamer SK, Kim GA, Taylor JM, O’Shea KM, Stein-horn RH, Farrow KN. Disrupted pulmonary artery cyclic guanosine monophosphate signaling in mice with hyperoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 50: 369–378, 2014.
26. Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PloS one 5: e14227, 2010.
27. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 154: 379–384, e371–372, 2009.
28. Movsesian MA, Kukreja RC. Phosphodiesterase inhibition in heart failure. Handbook Exp Pharmacol 237–249, 2011.
29. Murthy K, Savani RC, Lagatta JM, Zaniletti I, Wadhawan R, Truog W, Grover TR, Zhang H, Asselin JM, Durand DJ, Short BL, Pallotto EK, Padula MA, Dykes FD, Reber KM, Evans JR. Predicting death or tracheostomy placement in infants with severe bronchopulmonary dyspla-sia. J Perinatol 34: 543–548, 2014.
30. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodi-esterase type 5 improves contractility. Circulation 116: 238–248, 2007.
31. Nyp M, Sandritter T, Poppinga N, Simon C, Truog WE. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 32: 64–69, 2012.
32. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119: 408–416, 2009.
33. Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardio-vasc Res 82: 30–39, 2009.
34. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med 354: 2112–2121, 2006.
35. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 5: 79–86, 2012.
36. Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA. Echocar-diographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 31: 635–640, 2011.
37. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, Wessel DL. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 155: 841–847, e841, 2009.
38. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 67: 623–661, 2005.
39. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J 76: 1819–1825, 2012.
40. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysi-ology and therapeutics. Pharmacol Ther 122: 216–238, 2009.
41. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340: 1962–1968, 1999.
42. Vandenwijngaert S, Pokreisz P, Hermans H, Gillijns H, Pellens M, Bax NA, Coppiello G, Oosterlinck W, Balogh A, Papp Z, Bouten CV, Bartunek J, D’Hooge J, Luttun A, Verbeken E, Herregods MC, Herijgers P, Bloch KD, Janssens S. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PloS one 8: e58841, 2013.
43. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, Francis SH, Kukreja RC, Movsesian MA. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330: 884–891, 2009.
44. Velten M, Gorr MW, Youtz DJ, Velten C, Rogers LK, Wold LE. Adverse perinatal environment contributes to altered cardiac development and function. Am J Physiol Heart Circ Physiol 306: H1334–H1340, 2014.
45. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29: 297–310, 1999.
46. Walsh MC, Szefler S, Davis J, Allen M, Van Marter L, Abman S, Blackmon L, Jobe A. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117: S52–56, 2006.